http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102241770-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90348a429ffa25bbd39a647ab0d9173e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
| filingDate | 2011-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_268cbbbaf2e896edb3db9b178fe51dde http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0324e5ec03fbd8fc201c587a0de94786 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_545a4482bb9e79ccf14cae0fdf06d3b4 |
| publicationDate | 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102241770-B |
| titleOfInvention | Influenza virus M2-targeted ion channel protein VHH (Vibrio Harveyi Haemolysin) gene engineering antibody and coding gene and application thereof in preparation of anti-influenza-virus drug |
| abstract | The invention discloses an influenza virus M2-targeted ion channel protein VHH (Vibrio Harveyi Haemolysin) gene engineering antibody and a coding gene and application thereof in preparation of an anti-influenza-virus drug. The amino acid sequence of the VHH gene engineering antibody is shown as SEQ ID NO.1, and the coding gene sequence of the VHH gene engineering antibody is shown as SEQ ID NO.2. The antibody can be specifically combined with M2 ion channel protein molecules of influenza virus in a natural state and has an inhibition effect on influenza virus M2 wild type and amantadine drugresistant strain virus. A cell survival experiment shows that the antibody can take action through inhibiting functioning of an M2 ion channel. A mouse in vivo experiment verifies that a passive immunity M2-7AVHH antibody has a therapeutic protective effect on an influenza virus attacked mouse and can protect an animal from being invaded and attacked by lethal dose of influenza A/PR/8/34. The antibody can be used for developing the anti-influenza-virus drug such as a drug used for treating a subject who suffers form influenza or is in danger of suffering from the influenza. |
| priorityDate | 2011-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.